论文部分内容阅读
目的:检测耐药蛋白ABCG4在肺鳞癌、腺癌中的表达,分析其表达率与病理分级和临床分期间的关系,为研究ABCG4在肿瘤表达及耐药相关性提供基础。方法:采用免疫组织化学EnVinsion法、免疫荧光法检测ABCG4在肺鳞癌、腺癌中的表达和激光共聚焦显微镜观察其荧光定位。结果:ABCG4在肺鳞癌、腺癌中高表达,鳞癌总阳性率67.3%、腺癌总阳性率为81.4%,两者差异性显著(P=0.001);中分化、低分化鳞癌阳性率分别为41.7%、92.0%,差异性非常显著(P=0.000);腺癌中分化阳性率76.7%、低分化腺癌92.3%,差异性显著(P=0.033);鳞癌和腺癌的各临床分期的Kruskal-Wallis秩和检验差异性显著,P值分别为0.039、0.048。ABCG4主要定位在胞膜上和胞质中。结论:ABCG4在肺鳞癌、腺癌中高表达,表达的高低与病理分级、临床分期有关,为进一步研究ABCG4在肿瘤中的表达及可能耐药作用提供实验依据。
OBJECTIVE: To detect the expression of ABCG4 in lung squamous cell carcinoma and adenocarcinoma, and to analyze the relationship between ABCG4 expression and pathological grade and clinical stage, so as to provide a basis for studying ABCG4 in tumor expression and drug resistance. Methods: The expression of ABCG4 in lung squamous cell carcinoma and adenocarcinoma was detected by immunohistochemistry EnVinsion method and fluorescence localization by laser confocal microscopy. Results: The positive rates of ABCG4 in squamous cell carcinoma and adenocarcinoma were 67.3% for squamous cell carcinoma and 81.4% for adenocarcinoma (P = 0.001). The positive rates of moderately differentiated and poorly differentiated squamous cell carcinoma (P = 0.000). The positive rate of differentiation was 76.7% in adenocarcinoma and 92.3% in poorly differentiated adenocarcinoma (P = 0.033) Kruskal-Wallis rank sum test showed significant difference in clinical stage, with P values of 0.039 and 0.048, respectively. ABCG4 mainly located in the membrane and cytoplasm. CONCLUSION: ABCG4 is overexpressed in squamous cell carcinoma and adenocarcinoma. The expression of ABCG4 is correlated with the pathological grade and clinical stage. It provides an experimental basis for further studying the expression of ABCG4 in tumor and possible drug resistance.